Want to see LYEL full AI Analyst Report?
Lyell Immunopharma (LYEL) Ownership Overview
39.26% Insiders
6.98% Mutual Funds
32.69% Other Institutional Investors
6.04% ETFs
15.03% Public Companies and
Individual Investors
The ownership structure of Lyell Immunopharma (LYEL) stock is a mix of institutional, retail, and individual investors. Approximately 45.71% of the company’s stock is owned by Institutional Investors, 39.26% is owned by Insiders, and 15.03% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
Date | Name | Activity | Value |
|---|---|---|---|
Sep 10, 2026 | xxxxxxxxxxxxx | $6350 | |
Aug 25, 2026 | xxxxxxxxxxxxx | $149013 | |
Aug 25, 2026 | xxxxxxxxxxxxx | $15369 | |
Aug 25, 2026 | xxxxxxxxxxxxx | $22642 |
Recent Hedge Fund Trading Activity
Date | Firm | Activity | Value |
|---|---|---|---|
Jun 30, 2026 | xxxxxxxxxxxxx | $163008 | |
Jun 30, 2026 | xxxxxxxxxxxxx | $272711 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 3,247,162 | Insider | 13.25% | 38,836,058 | |
| 3,247,162 | Insider | 13.25% | 38,836,058 | |
| 2,774,980 | Insider | 11.32% | 33,188,761 | |
| 859,302 | Institution | 3.51% | 10,277,252 | |
| 699,473 | Institution | 2.85% | 8,365,697 | |
| 648,410 | Institution | 2.65% | 7,754,984 | |
| 459,426 | Institution | 1.87% | 5,494,735 | |
| 190,557 | Insider | 0.78% | 2,279,062 | |
| 146,413 | Institution | 0.60% | 1,751,099 | |
| 75,994 | Institution | 0.31% | 908,888 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 699,473 | Institution | 2.85% | 8,365,697 | |
| 648,410 | Institution | 2.65% | 7,754,984 | |
| 146,413 | Institution | 0.60% | 1,751,099 | |
| 71,141 | Institution | 0.29% | 850,846 | |
| 23,103 | Institution | 0.09% | 276,312 | |
| 21,526 | Institution | 0.09% | 257,451 | |
| 21,220 | Institution | 0.09% | 253,791 | |
| 18,000 | Institution | 0.07% | 215,280 | |
| 14,235 | Institution | 0.06% | 170,251 | |
| 9,320 | Institution | 0.04% | 111,467 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 604,461 | Institution | 2.47% | 7,821,725 | |
| 222,823 | Institution | 0.91% | 2,664,963 | |
| 163,755 | Institution | 0.67% | 2,118,990 | |
| 89,130 | Institution | 0.36% | 1,065,995 | |
| 66,893 | Institution | 0.27% | 816,095 | |
| 57,662 | Institution | 0.24% | 689,638 | |
| 53,059 | Institution | 0.22% | 686,583 | |
| 32,319 | Institution | 0.13% | 386,535 | |
| 30,080 | Institution | 0.12% | 46,624 | |
| 28,369 | Institution | 0.12% | 367,095 |
FAQ
Who Owns Lyell Immunopharma (LYEL)?
According to the latest TipRanks data, approximately 32.69% of the company's stock is held by institutional investors, 39.26% is held by insiders, and 15.03% is held by retail investors.
What percentage of Lyell Immunopharma (LYEL) stock is held by institutional investors?
According to the latest TipRanks data, approximately 32.69% of Lyell Immunopharma (LYEL) stock is held by institutional investors.
What percentage of Lyell Immunopharma (LYEL) stock is held by retail investors?
According to the latest TipRanks data, approximately 15.03% of Lyell Immunopharma (LYEL) stock is held by retail investors.
Who owns the most shares of Lyell Immunopharma (LYEL)?
ARCH Venture Fund XIII, L.P. owns the most shares of Lyell Immunopharma (LYEL).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.